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Abstract
Objectives—The impact of staphylococcal cassette chromosome mec (SCCmec) type on
mortality in methicillin-resistant Staphylococcus aureus (MRSA) infections remains unclear. The
objective of this study was to determine the association between SCCmec type and mortality in
MRSA bacteremia.
Methods—A cohort study of patients who were hospitalized with MRSA bacteremia was
conducted within a university health system. A multivariable logistic regression model was
developed to evaluate the association of SCCmec type with 30-day in-hospital mortality.
Results—Thirty-four of a total of 184 patients with MRSA bacteremia died, resulting in a
mortality rate of 18.5%. Adjusted risk factors for 30-day mortality included APRDRG Risk of
Mortality score (odds ratio [OR], 5.33; 95% confidence interval [CI], 2.28-12.4; P<0.001), white
blood cell count (OR, 1.09; 95% CI, 1.03-1.15; P=0.002), and malignancy (OR, 3.25; 95% CI,
1.17-9.02; P=0.02). On multivariable analyses, SCCmec II was not significantly associated with
mortality in patients with MRSA bacteremia (OR, 1.85; 95% CI, 0.69-4.92; P=0.22).
Conclusions—Mortality in MRSA bacteremia was independent of SCCmec type. SCCmec type
II is most likely a marker for disease severity rather than a direct mediator of mortality. Further
research is needed to elucidate the factors associated with poor clinical outcomes in MRSA
infections.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most common causes of
healthcare-associated infections worldwide and is associated with significant morbidity and
mortality.1 Methicillin resistance is mediated by acquisition of the mecA gene, which is
located within the staphylococcal cassette chromosome mec (SCCmec) element.2 In recent
years, MRSA has also emerged as an important cause of infections in the community
setting.3 Despite the lack of a uniform definition of community-associated MRSA (CA-
MRSA) in the literature, the term has usually been used to describe strains causing
infections in patients without recent contact with the healthcare environment.3 However,
recent epidemiologic evidence indicates that CA-MRSA strains are increasingly causes of
nosocomial infections,4 and that traditional epidemiologic definitions and risk factors may
no longer reliably differentiate between CA-MRSA and healthcare-associated MRSA (HA-
MRSA).5
From a molecular standpoint, CA-MRSA has typically been distinguished from HA-MRSA
by the SCCmec element, with SCCmec IV and V predominating in CA-MRSA strains and
SCCmec I, II, and III in HA-MRSA strains.3 Despite the increasing spread of CA-MRSA
into the hospital setting, the impact of SCCmec type on mortality in MRSA infections
remains unclear. Studies to date evaluating this association have demonstrated conflicting
results, most likely due to differences in patient populations, geographic region (e.g., United
States, Asia), anatomic site of infection, selection of reference groups, and lack of
multivariable analyses.6-14 Furthermore, only a proportion of these studies have focused
specifically on bacteremia,6, 8, 12-14 a major source of healthcare-associated infections due to
MRSA and one associated with significant morbidity and mortality.15 These studies have
also demonstrated conflicting results, and the majority evaluated patient populations outside
of the United States6, 12, 14 where different SCCmec types predominate.
We conducted this cohort study to determine the association between SCCmec type and
mortality in MRSA bacteremia. Specifically, we compared mortality in patients with S.
aureus bacteremia with SCCmec II as opposed to SCCmec IV, the predominant SCCmec
types in the United States.4
Patients and Methods
Study design and setting
This retrospective cohort study was conducted at two hospitals in the University of
Pennsylvania Health System (UPHS) in Philadelphia: the Hospital of the University of
Pennsylvania (HUP), a 725-bed academic tertiary care medical center, and Penn
Presbyterian Medical Center (PPMC), a 344-bed urban community hospital. The study was
approved by the institutional review board of the University of Pennsylvania.
Study population
All hospitalized patients with an episode of MRSA bacteremia occurring between 1
December 2007 and 31 May 2009 were identified through the HUP Clinical Microbiology
Laboratory, which processes all specimens obtained from patients at HUP and PPMC. All of
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these patients were subsequently included in the study. For patients with multiple blood
cultures positive for MRSA, only the first culture was included for analysis.
Microbiologic methods
Identification and susceptibility testing of S. aureus was performed and interpreted
according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Standard
susceptibility testing was performed using Vitek2. SCCmec typing was performed as
previously described.16 The vancomycin minimum inhibitory concentration (MIC) of all
isolates was determined by the Etest using Mueller-Hinton agar (BBL, BD Diagnostic
Systems, Franklin Lakes, NJ, USA)17 with reduced vancomycin susceptibility defined as an
Etest vancomycin MIC >1.0 μg/ml.18, 19 Vancomycin hetero-resistance was screened for
using the macro-Etest method using Etest GRD vancomycin/teicoplanin strips with brain
heart infusion agar17 and by growth on vancomycin-containing brain heart infusion agar;20 a
positive result for either screening test was confirmed by population analysis using a Spiral
Plater (Advanced Instruments, Norwood, MA, USA) and inoculation onto vancomycin brain
heart infusion agar (BBL).21 Detection of the genes encoding Panton-Valentine leukocidin
(PVL) was performed using real-time polymerase chain reaction using previously described
methods.22 Isolates were evaluated for accessory gene regulator (agr) dysfunction via delta-
hemolysin production using a beta-hemolysin disk.23
Data collection
Data were abstracted from the Pennsylvania Integrated Clinical and Administrative
Research Database (PICARD),24, 25 which includes demographic, laboratory, pharmacy, and
billing information. The following data were collected for all patients: baseline
demographics, origin at the time of hospital admission (i.e., physician referral, transfer from
another facility, or admission through the Emergency Department), previous admission to
UPHS in the 30 days prior to the culture date, hospital location at the time of infection (i.e.,
intensive care unit [ICU] or medical floor), nosocomial infection (date of the culture ≥48
hours after admission), white blood cell count (WBC) on the culture date, and All Patient
Refined-Diagnosis Related Group (APRDRG) Risk of Mortality and Severity of Illness
scores.26 Infections were classified as healthcare-associated if the date of the first positive
blood culture was ≥48 hours from the date of admission, or if the patient had been
previously hospitalized at HUP or PPMC in the 30 days prior to the culture date or was
admitted as a transfer from another institution. Otherwise, infections were classified as
community-onset. Data on the following conditions was collected in relation to the positive
blood culture date: diabetes mellitus, HIV infection, malignancy, renal insufficiency
(creatinine ≥2.0 mg/dL or the requirement of dialysis), solid organ or hematopoietic stem
cell transplantation, neutropenia (absolute neutrophil count <500/mm3), and receipt of an
immunosuppressive agent (e.g., corticosteroids, tacrolimus) in the prior 30 days. The
Charlson comorbidity index was calculated for each subject.27 Chart review was performed
to collect data on the presence of complicated infection (i.e., endocarditis, osteomyelitis,
septic arthritis, epidural and/or spinal abscess) and the presence of intravascular devices
(i.e., intravascular catheter, pacemaker or defibrillator, arteriovenous fistula or graft) prior to
the episode of bacteremia.
Information on all antimicrobial therapy administered during the same hospitalization was
collected, including the time of receipt in relation to the culture date. Antibiotics were
considered to be appropriate in relation to treatment of the episode of MRSA bacteremia if
they were determined to be active in vitro against the isolate via standard susceptibility
testing. The primary outcome was crude in-hospital 30-day mortality, defined as death in the
hospital from any cause occurring in the 30 days after the date of the first positive blood
culture.
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Continuous variables were compared using the Student’s t-test or Wilcoxon rank-sum test
and categorical variables were compared using the χ2 or Fisher’s exact test. Bivariable
analyses were performed to determine the association between SCCmec type and 30-day in-
hospital mortality, with the primary exposure of interest being SCCmec type II. Stratified
analyses were conducted to elucidate where confounding and interaction were likely to exist
in multivariable analyses, using the Mantel-Haenszel test for summary statistics.28 In
particular, location in the ICU, hospital of admission, and healthcare-associated infection
were designated a priori as potential effect modifiers of interest. Effect modification was
assumed to be present when the test for heterogeneity between the odds ratios (ORs) for
different strata yielded a P value <0.05. The Mantel-Haenszel test for summary statistics28
was used to evaluate the effects of each variable of interest as a possible confounder.
Adjusted ORs with 95% confidence intervals (CI) were calculated using multiple logistic
regression for the outcome of 30-day in-hospital mortality. A stepwise selection procedure
was used for all multivariable analyses, with variables with P values <0.20 on bivariable
analyses or noted to be confounders on stratified analyses considered as candidate variables
and maintained in the final model if their inclusion resulted in a ≥15% change in the effect
measure for the primary association of interest or were statistically significant on likelihood
ratio testing.29
For all calculations, a 2-tailed P value <0.05 was considered to be significant. All statistical
calculations were performed using commercially available software (STATA version 11.0;
StataCorp LP, College Station, Texas, USA).
Results
Study population
A total of 184 unique patients with MRSA bacteremia were identified during the study
period. The distribution of SCCmec type among isolates was as follows: 109 (59.2%) with
SCCmec II and 75 (40.8%) with SCCmec IV. Baseline clinical and demographic
characteristics of patients with MRSA bacteremia are shown in Table 1. Patients with
bacteremia due to MRSA harboring SCCmec II compared to SCCmec IV were older (mean
age 62.8 and 55.1 years, respectively; P=0.002), had a higher APRDRG Risk of Mortality
score at the time of MRSA isolation (mean 2.6 and 1.8, respectively; P=0.004), and had a
significantly longer length of stay prior to the culture date (11.1 and 2.49 mean days,
respectively, P=0.02).
Microbiologic characteristics
Isolates with SCCmec II versus SCCmec IV were more likely to be characterized by
reduced vancomycin susceptibility (51.4% and 22.7%, respectively; P<0.001)30 and less
likely to be PVL positive (0.9% and 68.0%, respectively, P<0.001). There were no
significant differences in the proportion of isolates with SCCmec II and SCCmec IV that
were characterized by vancomycin hetero-resistance (6.4% and 2.7%, respectively; P=0.36)
or agr dysfunction (16.5% and 10.7%, respectively; P=0.29).
In regard to antimicrobial susceptibility rates, MRSA isolates with SCCmec IV compared to
those with SCCmec II demonstrated significantly higher rates of susceptibility to
clindamycin (86.7% and 4.6%, respectively; P<0.001) and levofloxacin (41.3% and 0.92%,
respectively; P<0.001). However, there were no significant differences in susceptibility rates
for isolates with SCCmec IV versus SCCmec II for tetracycline (94.7% and 98.2%,
respectively; P=0.23) and trimethoprim-sulfamethoxazole (94.7% and 99.1%, respectively;
P=0.16).
Han et al. Page 4










Risk factors for 30-day in-hospital mortality
A total of 34 patients died while hospitalized for MRSA bacteremia, resulting in a crude
mortality rate of 18.5%. The mortality rate was 23.9% and 10.7% for patients with MRSA
isolates characterized by SCCmec II and SCCmec IV, respectively (P=0.03). Results of
bivariable analyses of risk factors associated with in-hospital mortality are given in Table 2.
The majority of patients received appropriate antibiotics, specifically 99.3% of patients who
survived and 96.9% of patients who died during hospitalization, with vancomycin the most
commonly administered initial antibiotic (86.7% and 91.2%, respectively; P=0.58).
On multivariable analyses of risk factors for 30-day in-hospital mortality (Table 3), there
was no significant effect modification by location in the ICU (P=0.26), hospital of admission
(P=0.21), or healthcare-associated infection (P=0.16). The unadjusted OR between SCCmec
II and mortality was 2.62 (95% CI 1.06-7.12, P=0.03). On multivariable analyses,
independent risk factors for in-hospital mortality included APRDRG Risk of Mortality score
(OR 5.33, 95% CI 2.28-12.4, P<0.001), malignancy (OR 3.25, 95% CI 1.17-9.02, P=0.02),
and WBC count on the culture date (OR 1.09, 95% CI 1.03-1.15, P=0.002). After controlling
for confounders, SCCmec II was not significantly associated with greater 30-day in-hospital
mortality (OR 1.85, 95% CI 0.69-4.92, P=0.22).
Discussion
In this cohort study of patients with MRSA bacteremia, we found that SCCmec type,
specifically SCCmec II compared to SCCmec IV, was not significantly associated with
mortality. Furthermore, isolates harboring SCCmec IV had higher susceptibility rates to
clindamycin and levofloxacin compared to those with SCCmec II. The results of our study
also demonstrated that a higher standardized mortality risk score, the presence of
malignancy, and a higher white blood cell count were independent risk factors for mortality
in MRSA bacteremia.
Previous studies have demonstrated conflicting results in regard to the role of SCCmec type
on mortality in infections due to MRSA.6-14 In a study evaluating patients with MRSA skin
and soft tissue infections,11 SCCmec II was associated with greater mortality compared to
both MRSA with other SCCmec types (primarily IVa) and methicillin-susceptible S. aureus
(MSSA). In a larger study of 465 MRSA isolates responsible for skin and soft tissue
infections from a phase IV clinical trial,10 clinical and microbiologic outcomes, including
mortality, were independent of SCCmec type. A study evaluating 100 community-associated
MRSA isolates from various sources (e.g., respiratory tract, bacteremia) demonstrated
greater mortality in the SCCmec II/III group compared to the SCCmec IV group (i.e., two
patients and one patient died during hospitalization, respectively), although there was no
difference in clinical or microbiologic success rates.7 However, all of these studies were
limited to bivariable analyses. Finally, a study evaluating clinical outcomes in MRSA
pneumonia9 found that SCCmec II was associated with increased mortality on bivariable
analysis; however, this association was not significant on subsequent multivariable analyses.
Studies evaluating the impact of SCCmec type on mortality exclusively in MRSA
bacteremia,6, 8, 12-14 as was the focus of our study, have also demonstrated conflicting
results, as well as significant heterogeneity in regard to patient population, ascertainment of
potential confounders, geographic region, and use of multivariable analyses. A few
studies6, 8 have found increased mortality with MRSA strains harboring SCCmec II, but
these were limited by comparison to MSSA only,6 failure to account for time to receipt of
appropriate antimicrobial therapy,8 and evaluation of only community-onset infections.6
Other studies12-14 have demonstrated no association between SCCmec type and mortality,
although these were limited by use of bivariable analyses only,12 or evaluated a patient
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population from a different geographic region than the present study (i.e., Asia versus the
United States)12, 14 where different SCCmec types predominate. Our study demonstrated no
association between SCCmec II and mortality, and to our knowledge, is the largest to date
evaluating the impact of SCCmec type on mortality in MRSA bacteremia using
multivariable analyses. The results are further strengthened by the comprehensive capture of
potential confounders, including time to receipt of appropriate antimicrobial therapy,
standardized severity of illness and risk scores, and presence and/or removal of intravascular
devices.
Factors that are likely to contribute to the relationship between MRSA infection and
mortality include bacterial virulence and fitness, host factors including comorbidities and
severity of illness, and the receipt of early and appropriate antimicrobial therapy.31 It is
possible that SCCmec II may be a marker of illness severity and/or greater exposure to the
healthcare system rather than a direct mediator of mortality, and indeed, in our study and
others,4, 7, 14 SCCmec II compared to SCCmec IV was associated with significantly higher
standardized severity of illness scores and longer hospital lengths of stay prior to isolation of
MRSA. Therefore, in the hospitalized population, which is generally characterized by a
greater severity of illness and the presence of more comorbidities compared to the
community population, SCCmec II may not have a direct causal effect on mortality.Along
these lines, in the present study, while SCCmec II was a risk factor for mortality on
bivariable analyses compared to SCCmec IV, after adjustment for potential confounders
including a standardized score for mortality risk, there was no association between SCCmec
type and mortality.
The receipt of appropriate antimicrobial therapy (e.g., one or more agents that are active in
vitro against the isolate), as well as timing of receipt, have been shown to decrease mortality
in MRSA bacteremia.32 Notably, in our study, the majority of patients with bacteremia due
to MRSA with both SCCmec II and SCCmec IV received appropriate antimicrobial therapy
(98.7% and 99.1%, respectively; P>0.99). Furthermore, there was no significant difference
in time to administration of appropriate antimicrobial therapy in patients with bacteremia
due to MRSA with either SCCmec II or SCCmec IV (mean of 16.1 and 15.8 hours,
respectively, P=0.31).
In regard to organism factors, evidence suggests that MRSA strains with SCCmec IV may
exhibit enhanced virulence and/or fitness compared to those harboring SCCmec II.33, 34
Indeed, some studies have demonstrated an increased risk of metastatic infection with
SCCmec IV,8, 13 although this did not translate to an increased risk of persistent
bacteremia.13 Interestingly, SCCmec II was associated with elevated vancomycin MIC in
our study,30 although this did not increase mortality in the final multivariable model.
There are several potential limitations of our study. We were unable to ascertain
pharmacologic data on therapeutic drug monitoring in patients receiving vancomycin.
Selection bias is a potential concern; however, patients with MRSA bacteremia were
identified through the Clinical Microbiology Laboratory which processed and cultured all
specimens obtained at HUP and PPMC during the study period, thereby minimizing the
likelihood of excluding potential microbiologic isolates. Finally, the present study was
conducted in a single healthcare system, and these results may not be generalizable to other
institutions or geographic locations.
In conclusion, we found that after adjustment for relevant confounders, mortality in MRSA
bacteremia is independent of SCCmec type. It is clear that the epidemiology of MRSA is
complex and evolving, and strains possessing SCCmec IV are an increasing cause of
infections in the nosocomial setting, including invasive infections such as bacteremia.
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Further research is needed to elucidate potentially modifiable host and organism factors
associated with mortality in MRSA infections.
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Age, mean years (SD) 63 (15.7) 55 (17.4) 0.002
Female sex 44 (40.4) 29 (38.7) 0.82
White race 71 (62.7) 35 (45.9) 0.07
HUP 85 (78.0) 43 (57.3) 0.003
Emergency Department admission 43 (39.5) 48 (64.0) 0.001
Nosocomial onset 38 (34.9) 12 (16.0) 0.007
Healthcare-associated 76 (69.7) 36 (48.0) 0.003
APRDRG Risk of Mortality score
b
, mean (SD)
2.3 (0.9) 1.8 (1.1) 0.004
HIV 2 (1.8) 7 (9.3) 0.03
Malignancy 32 (29.4) 13 (17.3) 0.06
Intravascular device 56 (51.4) 23 (30.7) 0.005
In-hospital length of stay prior to culture date,
mean days (SD)
11.1 (52.9) 2.5 (8.8) 0.02
30-day in-hospital mortality 26 (23.9) 8 (10.7) 0.03
SD, standard deviation; HUP, Hospital of the University of Pennsylvania; APRDRG, All Patient Refined-Diagnosis Related Group.
a
Data are presented as numbers (percentages) except where noted.
b
Risk of patient death as based on DRG. The four subclasses are numbered sequentially from 1 to 4 indicating respectively, minor, moderate,
major, or extreme risk of mortality.










Han et al. Page 11
Table 2













Age, mean years (SD) 58.7 (16.9) 64.1 (15.7) N/A 0.10
Female sex 57 (38.0) 16 (47.1) 1.45 (0.63-3.28) 0.33
White race 87 (56.8) 19 (50.0) 0.64 (0.28-1.44) 0.26
PPMC admission 51 (34.0) 5 (14.7) 0.33 (0.10-0.95) 0.04
Physician referral on admission 27 (18.0) 3 (8.8) 0.44 (0.08-1.59) 0.30
Nosocomial infection 39 (26.0) 11 (32.4) 1.36 (0.55-3.23) 0.52
Total duration of bacteremia from
culture date, mean days (SD)
3.5 (4.6) 3.6 (5.6) N/A 0.52
Receipt of appropriate antibiotic(s) 147 (99.3) 31 (96.9) 0.21 (0.003-17.1) 0.33
Days to receipt of appropriate
antibiotics, mean (SD)
0.70 (1.2) 0.48 (0.63) N/A 0.60




1.9 (1.0) 2.8 (0.54) N/A <0.001




2.4 (0.64) 2.9 (0.41) N/A <0.001
Charlson Comorbidity score, mean
(SD)
4.4 (4.6) 4.1 (3.4) N/A 0.97
Intravascular device 64 (42.7) 15 (44.1) 1.06 (0.46-2.39) >0.99
Removal of intravascular device 47 (73.4) 12 (80.0) 1.45 (0.33-8.91) 0.75
Complicated infection 52 (34.7) 10 (29.4) 0.79 (0.31-1.86) 0.69
Diabetes mellitus 46 (30.7) 11 (32.4) 1.08 (0.44-2.54) 0.84
Malignancy 32 (21.3) 13 (38.2) 2.28 (0.94-5.38) 0.05
Renal insufficiency 42 (28.2) 13 (38.2) 1.58 (0.66-3.65) 0.30
Neutropenia 4 (11.8) 7 (4.7) 2.70 (0.54-11.4) 0.13
Transplant (solid organ or
hematopoietic stem cell)
19 (12.7) 2 (5.9) 0.43 (0.05-1.95) 0.38
Receipt of any immunosuppression
≤30 days prior to the culture date
15 (10.0) 8 (23.5) 2.77 (0.91-7.79) 0.04
ICU location on culture date 31 (20.7) 15 (44.1) 3.03 (1.27-7.10) 0.01
WBC count, mean X 109/L (SD) 12.4 (7.8) 16.6 (12.0) N/A 0.07
Reduced vancomycin
susceptibility
61 (40.7) 12 (35.3) 0.80 (0.33-1.83) 0.56
hGISA 7 (4.7) 2 (5.9) 1.28 (0.12-7.13) 0.67
PVL 46 (30.7) 6 (17.7) 0.49 (0.15-1.31) 0.15
agr dysfunction 20 (13.3) 6 (17.7) 1.39 (0.42-4.03) 0.59
OR, odds ratio; CI, confidence interval; SD, standard deviation; N/A, not applicable; PPMC, Penn Presbyterian Medical Center; APRDRG, All
Patient Refined-Diagnosis Related Group; ICU, intensive care unit; WBC, white blood cell count; hGISA, glycopeptide heterointermediate
Staphylococcus aureus; PVL, Panton Valentine leukocidin; agr, accessory gene regulator.
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a
Data are presented as numbers (percentages) except where noted.
b
ORs unavailable for continuous variables.
c
Risk of patient death and severity of illness as based on DRG. The four subclasses are numbered sequentially from 1 to 4 indicating respectively,
minor, moderate, major, or extreme risk of mortality or severity of illness.
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Table 3
Final multivariable model of risk factors associated with in-hospital mortality in
methicillin-resistant Staphylococcus aureus bacteremia
Variable OR (95% CI) P Value
APRDRG Risk of Mortality score
a 5.33 (2.28-12.4) <0.001
Malignancy 3.25 (1.17-9.02) 0.02
WBC count on culture date 1.09 (1.03-1.15) 0.002
SCCmec II 1.85 (0.69-4.92) 0.22
Neutropenia 4.52 (0.77-26.4) 0.09
OR, odds ratio; CI, confidence interval; APRDRG, All Patient Refined-Diagnosis Related Group; WBC, white blood cell count.
a
Risk of patient death based on DRG. The four subclasses are numbered sequentially from 1 to 4 indicating respectively, minor, moderate, major,
or extreme risk of mortality.
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